ArticleScientific reports2025
Psychometric properties of the Italian version of scale for outcomes in Parkinson's disease psychiatric complications in Parkinson disease.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The Scales for Outcomes in Parkinson's disease-Psychiatric Complications (SCOPA-PC) is a validated tool to score psychotic and compulsive symptoms in Parkinson's disease (PD). We translated into Italian the SCOPA-PC and evaluated its psychometric properties and clinical correlates in different subgroups of PD patients. The scale underwent translation, back-translation, and cognitive pretesting before being administered to a calculated sample of 135 PD patients. All patients underwent a clinical interview, motor evaluation, cognitive screening test, behavioral and functional scales. We explored SCOPA-PC feasibility, acceptability, internal consistency, convergent validity, known-groups validity, and test-retest reliability. The mean SCOPA-PC score was 1.99 ± 2.09. The internal consistency was acceptable (α = 0.631); corrected item-total correlation was > 0.45 for most items. The significant and moderate correlation of the SCOPA-PC with other tools evaluating psychiatric symptoms indicated adequate convergent validity of the scale. The factor analysis disclosed two factors, with total variance equal to 50.19%. The reliability of SCOPA-PC was high especially in cognitively preserved patients not on medications for dementia, depression, psychosis and anxiety. The SCOPA-PC is a rapid and reliable screening tool for assessing psychotic and compulsive symptoms in PD. Our data support a role for the SCOPA-PC as a screening scale in early, non-demented PD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.